Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa
Abstract
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committed step of lipid A biosynthesis. Achaogen conducted an extensive research campaign to discover novel LpxC inhibitors with activity against Pseudomonas aeruginosa .
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2019
- Source ID
- 10.1128/aac.00977-19
Entities
People
- Adrian Jubb
- Alisa W. Serio
- Amanda Burek
- Cat M. Haglund
- Chris Pillar
- Christy Hebner
- Danielle Hall
- Darrin Hildebrandt
- Eliana Armstrong
- Frederick Cohen
- Grace Lee
- Kevin M. Krause
- Lee Swem
- Logan D. Andrews
- Lynn Miesel
- Mary Thwaites
- Meredith Hackel
- Ryan T. Cirz
- Timothy D. Machajewski
- Timothy R. Kane
- Vincent Nieto
Organizations
- Defense Threat Reduction Agency
- National Institute of Allergy and Infectious Diseases
- Wellcome Trust